Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
LivaNova PLC (LIVN) is a global leader in medical technology innovation, specializing in life-supporting cardiopulmonary solutions and neuromodulation therapies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Track all official LivaNova press releases, earnings reports, and product development announcements in one centralized resource. Our curated news feed covers critical developments including FDA clearances, international expansion efforts, and partnerships shaping the future of cardiac surgery and neurological treatment technologies.
Key updates feature progress in extracorporeal circulation systems, enhancements to vagus nerve stimulation therapies, and sustainability initiatives across global manufacturing operations. The platform serves as a vital tool for monitoring how LivaNova’s innovations in heart-lung machines and depression treatment devices impact both patient outcomes and shareholder value.
Bookmark this page for immediate access to verified information about LIVN’s market position, intellectual property developments, and leadership changes. Stay informed about the medical technology pioneer driving advancements in critical care through its merged heritage of European and American engineering excellence.
LivaNova (Nasdaq: LIVN), a leading medical technology company, announced that its CEO, Vladimir Makatsaria, will participate in a fireside chat at the Goldman Sachs Healthcare Conference.
The event will take place in Miami, Florida, on June 10 at 1:20 p.m. Eastern Time. A webcast will be available for those who register on the LivaNova website.
The webcast will also be accessible as a replay for 90 days following the live presentation.
LivaNova PLC (Nasdaq: LIVN) reported strong first-quarter 2024 results with revenue of $294.9 million, a 12.0% increase, and adjusted diluted earnings per share of $0.73. The company raised its full-year 2024 revenue guidance to grow between 6-7% on a constant-currency basis. LivaNova achieved positive trial outcomes in the OSPREY clinical study for obstructive sleep apnea. The company closed a private offering of $345.0 million convertible senior notes due 2029 and repurchased $230.0 million exchangeable senior notes due 2025.
LivaNova PLC announced the appointment of Ahmet Tezel, Ph.D., as Chief Innovation Officer, effective May 13, 2024. Tezel will lead the development of new technologies leveraging his 20+ years of experience in research and development. His role will enhance the Company's innovation capabilities in neurological and cardiac health.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
